Equity Overview
Price & Market Data
Price: $0.183
Daily Change: $0.00 / 0.00%
Daily Range: $0.15 - $0.183
Market Cap: $53,744,644
Daily Volume: 35,675
Performance Metrics
1 Week: -16.75%
1 Month: -32.31%
3 Months: -73.06%
6 Months: -77.55%
1 Year: -84.78%
YTD: -79.12%
Details
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.